Please read and agree to the terms and conditions of this site.
@xconomy.com 4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com 4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com 5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com 5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com 5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com 5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com 5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M